Correlation Between Depression Scores and Serum NF-ĸB/NLRP3 Axis, Biotinidase, and HMGB After Treatment With Isotretinoin in Patients With Acne Vulgaris

Last updated: March 1, 2025
Sponsor: Mostafa Bahaa
Overall Status: Completed

Phase

3

Condition

Scalp Disorders

Acne

Inflammatory Comedones

Treatment

ISOtretinoin 20 MG

Clinical Study ID

NCT06242288
659874
  • Ages 18-40
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Acne is a chronic inflammatory disease of the pilosebaceous unit resulting from androgen-induced increased sebum production, altered keratinization, inflammation, and bacterial colonization of hair follicles on the face, neck, chest, and back by, Cutibacterium acnes. Although all age groups can be affected, it is primarily a disease of adolescence. Treatment selection is based on disease severity, patient preference, and tolerability. Isotretinoin is drug of chioce used for moderate and severe acne. Isotretinoin results in a significant reduction in sebum production, influences comedogenesis, lowers surface and ductal c. acnes and has anti-inflammatory properties. Biotin deficiency may be caused by insufficient dietary uptake of biotin, drug- vitamin interactions and increased biotin catabolism during pregnancy and in smokers. Biotin deficiency can also be precipitated by decreased activities of biotinidase, which plays a central role in the intestinal absorption of biotin

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age of 19 to 35 years. Body mass index (BMI) of 18.5 to 23 kg/m2. Acne vulgaris (global acne scoring more than 18)

Exclusion

Exclusion Criteria:

Use of oral steroids, oral contraceptives, oral vitamin A derivatives, antibiotics, or herbal medicines that may affect the test results during the last 4 weeks.

Alcohol drinking within the last week. Smoking. Pregnancy or lactation. Judgement that physical or mental testing is not appropriate for the clinical trial.

Participation in other clinical trials that may affect this t

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: ISOtretinoin 20 MG
Phase: 3
Study Start date:
January 30, 2024
Estimated Completion Date:
January 20, 2025

Connect with a study center

  • Tanta Unuversity

    Tanta, 31527
    Egypt

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.